ClinicaliQ Trial Snapshot
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma — Recruiting • Phase III • Oncology • NCT07522073.
- What is being tested: The addition of INCB161734 (a KRAS G12D inhibitor) to standard chemotherapy versus chemotherapy alone in patients with metastatic pancreatic cancer harbouring the KRAS G12D mutation.
- Patient eligibility overview: Previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDAC) confirmed to have KRAS G12D mutation are eligible for randomisation to either treatment arm.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Eligibility Snapshot
- : * Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation * No prior systemic treatment in the metastatic setting * ECOG Performance status 0-1 * Adequate organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.